Antibody-Armed Platelets for the Regenerative Targeting of Endogenous Stem Cells
Antibody-Armed Platelets for the Regenerative Targeting of Endogenous Stem Cells
复制标题
用于内源干细胞再生靶向的抗体血小板
DOI：
10.1021/acs.nanolett.8b04970
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Ke Cheng
中科院分区：
文献类型：
--
作者：
Deliang Shen;zhenhua li;Shiqi Hu;Ke Huang;Teng Su;Hongxia Liang;Feiran Liu;Ke Cheng
干细胞疗法在治疗急性和慢性缺血性心脏病方面已显示出前景。然而，目前的疗法受到损伤组织中注射细胞的低保留和不良整合的限制。利用血小板的天然梗死归巢能力，我们设计了CD 34抗体连接血小板（P-CD 34），以捕获循环中CD 34阳性的内源性干细胞并将其引导至受损心脏，在体外，P-CD 34可以结合受损的血小板并捕获全血中的内源性干细胞。在急性心肌梗死的小鼠模型中，静脉给药后，P-CD 34在受损心脏中积累，导致受损心脏中内源性CD 34干细胞的浓度，用于有效的心脏修复。这代表了内源性干细胞治疗的新技术。
Stem cell therapies have shown promise in treating acute and chronic ischemic heart disease. However, current therapies are limited by the low retention and poor integration of injected cells in the injured tissue. Taking advantage of the natural infarct-homing ability of platelets, we engineered CD34 antibody-linked platelets (P-CD34) to capture circulating CD34-positive endogenous stem cells and direct them to the injured heart.In vitro, P-CD34 could bind to damaged aortas and capture endogenous stem cells in whole blood. In a mouse model of acute myocardial infarction, P-CD34 accumulated in the injured heart after intravenous administration, leading to a concentration of endogenous CD34 stem cells in the injured heart for effective heart repair. This represents a new technology for endogenous stem cell therapy.